Indivisible Partners Purchases New Stake in Gilead Sciences, Inc. $GILD

Key Points

• Indivisible Partners bought a new stake of 9,379 shares in Gilead during Q4 (≈$1.15M); institutional investors now own about 83.67% of the stock, with large additions from firms like Massachusetts Financial Services and Vanguard.
• Several analysts raised targets recently (e.g., Scotiabank to $177, JPMorgan to $160), leaving a MarketBeat consensus rating of “Moderate Buy” and a consensus target price of $157.35.
• Gilead beat Q4 expectations with EPS of $1.86 (vs. $1.83 est.) and revenue of $7.93B (vs. $7.68B est.), and issued FY2026 EPS guidance of 8.45–8.85, near the Street’s average of 8.62.

Indivisible Partners purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 9,379 shares of the biopharmaceutical company's stock, valued at approximately $1,151,000.

Several other hedge funds have also recently bought and sold shares of the business. Massachusetts Financial Services Co. MA grew its holdings in Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company's stock valued at $518,368,000 after purchasing an additional 4,113,999 shares in the last quarter. Vanguard Group Inc. grew its holdings in Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company's stock valued at $14,863,487,000 after purchasing an additional 2,113,692 shares in the last quarter. First Trust Advisors LP grew its holdings in Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company's stock valued at $342,910,000 after purchasing an additional 1,874,508 shares in the last quarter. Invesco Ltd. grew its holdings in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock valued at $1,680,505,000 after purchasing an additional 1,618,453 shares in the last quarter. Finally, Danske Bank A S acquired a new stake in Gilead Sciences during the 3rd quarter valued at $133,049,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GILD. Scotiabank raised their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the company a "sector outperform" rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $150.00 to $160.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Daiwa Securities Group raised their price target on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, February 25th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Finally, Rothschild & Co Redburn lifted their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a research note on Tuesday, February 17th. Twenty-four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $157.35.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly outlook: Analysts’ previews expect steady Q1 2026 growth and the company has given FY26 EPS guidance consistent with continued revenue momentum, supporting the bullish case for near‑term earnings stability. Gilead Sciences Q1 2026 Earnings Preview: Steady growth ahead?
• Positive Sentiment: Governance cleared: Shareholders backed the board and executive pay plans at the 2026 meeting, reducing near‑term proxy risk and governance uncertainty for investors. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Positive Sentiment: Pipeline expansion via collaboration: Galapagos (Lakefront) announced a collaboration agreement with Gilead to advance a T‑cell engager, expected to close in Q2—this adds potential early‑stage oncology upside to Gilead’s R&D footprint. Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Yeztugo adoption is rising: Use of Gilead’s twice‑yearly HIV prevention shot has climbed since launch, which supports longer‑term PrEP revenue potential, though uptake remains variable. Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Claims on EPS impact: An advocacy group (AHF) published that Gilead’s EPS could surge due to state AIDS‑drug program disruptions; this could lift sentiment if confirmed by results but is disputed and should be weighed against company filings. Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
• Neutral Sentiment: Analyst commentary: Roundups of healthcare analyst takes mention Gilead alongside peers but add little new near‑term catalyst; useful for tone but not material changes to consensus. Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD), AC Immune SA (ACIU) and Gilead Sciences (GILD)
• Negative Sentiment: Partner program shift: Arcus halted a Phase 3 lung trial and Gilead narrowed option rights on their collaboration, reducing future optionality on that program and signaling Gilead may be reprioritizing certain oncology bets—a potential long‑term negative to pipeline breadth. Arcus Biosciences Rethinks Growth After STAR-121 Exit And Gilead Shift

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ:GILD opened at $136.30 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a fifty day simple moving average of $139.87 and a 200 day simple moving average of $132.79. The firm has a market cap of $169.18 billion, a PE ratio of 20.13, a price-to-earnings-growth ratio of 1.77 and a beta of 0.31. Gilead Sciences, Inc. has a 12-month low of $95.29 and a 12-month high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business's revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 8.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the completion of the transaction, the chief financial officer owned 167,779 shares of the company's stock, valued at $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 63,000 shares of company stock valued at $9,238,250 over the last 90 days. 0.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.